Minerva Neurosciences | NERV - Net Income


Minerva Neurosciences reported $1.44M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Adma Biologics USD 37.82M 7.51M Jun/2026
ALKERMES USD 16.29M 15.79M Sep/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
AstraZeneca USD 3.12B 610M Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Cipla INR 8.78B 884.9M Sep/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.01M 663K Jun/2026
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
J&J USD 210M 5.32B Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 3.24B 3.49B Sep/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
Takeda JPY 192.43B 79.23B Sep/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024